Criteria to qualify for study: Drug used in study:
  • Symptomatic and measurable disease; ECOG <1

LYM 188

A Phase 1b/ll study of safety, tolerability and efficacy of APG-2575 alone or in combination with other therapeutic agents in patients with Waldenstrom Macroglobulinemia.

https://clinicaltrials.gov/ct2/results?cond=&term=NCT04260217
Criteria to qualify for study: Drug used in study:
  • Confirmed MYD88 and CXCR4 mutations

LYM 165

A Phase 1b Trial of Mavorixafor, an oral CXCR4 Antagonist, in combination with Ibrutinib in patients with Waldenstrom’s Macroglobulinemia (WM) whose tumors express mutations of MYD88 and CXCR4

https://clinicaltrials.gov/ct2/show/NCT04274738